Infinity Mining Limited · ASX:IMI
Infinity Mining — IM Medical — Bell Potter Small Cap conference (November 2007)
16 slides from Infinity Mining's conference presentation, November 2007
Slide 1: Update on Business Strategy: Future in Health Management
UPDATE ON BUSINESS STRATEGY Future In Health Management 2007 - 2008 Nov 2007
Slide 2: Disclaimer
Disclaimer Except for historical information, this presentation may contain forward – looking statements that reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market co
Slide 3: Capital Structure
Capital Structure Shares on Issue 1,198 million Top 20 Shareholders 25% – Top 2 shareholders ( Allan Blood & Cardanal P/L ) hold 11.3% Market Capitalisation $54 million Share Price Range (12 months) $0.014 to $0.064 Cash in Bank $3.2 million
Slide 4: Our Product
Our Product Exclusive technology identifies and measures risk factors for cardiovascular disease (CVD) Cardiovascular disease affects 1 in 5 Australians and kills 1 person every 10 minutes New ECG technology gives cardiologists fast and reliable tools to diagnose heart conditions. The WHO estimates
Slide 5: Our Strategy 2007/08
Our Strategy 2007/08 Maintain & expand Maintain & expand Complete Research Enter Consumer Clinic business Workplace business studies Retail market Establish Private International Launch Integration with New products, new Health Fund market Intelliheart revenue streams
Slide 6: Our Clinic Business
Our Clinic Business Feedback from users of Intelliheart test prompted changes to the format of the results provided to GPs Changes to report format stalled the progress within clinics for a number of months. Conversion of ‘signed’ clinics to ‘operational’ clinics underway Confident of achieving 200
Slide 7: Our Workplace Business
Our Workplace Business Greater awareness by corporate community of employee losses due to Cardiovascular Disease. Creates more opportunities for IM Medical. Large number of submissions to corporate users in pipeline Revenue ranges from $75 to $275 per assessment The Australasian market place has mor
Slide 8: Our Retail Business
Our Retail Business Current sales initiatives have already commenced in gymnasiums with the Consumer offer Will be sold nationally through hundreds of high-profile pharmacy outlets, gymnasiums and weight loss centres Live smarter
Slide 9: Our Business with Private Health Funds
Our Business with Private Health Funds Opportunity provided by legislation allowing rebates for preventative health a perfect “fit” to help funds manage high-risk customers Active discussions with several funds to trial Intelliheart amongst its members Competition in funds industry will promote inno
Slide 10: Our International Market
Our International Market Secured Pilot program with major Italian hospital under supervision of prominent Italian cardiologist. Results from this pilot will be assessed for Possible inclusion of Intelliheart test in the Italian health system Active discussions with hospitals and research organisatio
Slide 11: Our Research Studies
Our Research Studies Three major studies either currently underway or about to commence: •Monash Research Study to establish Intelliheart as the non-invasive technology of choice for assessing the presence and progression of coronary artery disease •Northern Hospital study will compare Cardanal with
Slide 12: Intelliheart and Cardanal technology integration
• Integration with Completed October 2007 • Analyses the heart’s electrical activity over considerably longer period • Much fuller picture than conventional ECG • Allows real time internet transmission and storage of ECG signals • Remote diagnosis of heart problems • The Cardanal Predictive Index (C
Slide 13: Our Revenue 2007-08
Our Revenue 2007-08 REVENUE PROFILE LOCAL MARKET $ PER TEST INTELLIHEART Medical Clinics Complementary Allied Health Pharmacy Range From $50 to $300 Gyms & Weight Loss Private Health Fund Workplace CARDANAL Service & License fee + Storage fee per test + Sending/Retrieving fee per ECG INTERNATIONAL I
Slide 14: Our Achievements in 2007
Our Achievements in 2007 Established Intelliheart nationally in clinic environment First stage of unique technology integrated into the new upgraded test October 2007. Prepared Cardanal Predictive Index software ready for local and international release Potential for Intelliheart confirmed by Monash
Slide 15: Our Potential
Our Potential Cutting edge technology in one of health industry’s biggest markets CVD and other chronic diseases taking increasing share of health spending IM Medical innovations co-incide with initiatives for preventative health by governments and insurers Global opportunity through Intelliheart an
Slide 16: During this presentation, three Australians have lost their lives to heart disease
During this presentation, three Australians have lost their lives to heart disease
IM Medical — Bell Potter Small Cap conference (November 2007) on 6ix